Natco Pharma Board to Consider Unaudited Results and Dividend

The Board of Directors of Natco Pharma is scheduled to meet on November 14, 2025, to consider the unaudited financial results for the quarter and half-year ended September 30, 2025. The board will also consider a 2nd interim dividend, if any, for the financial year ending 2025-26. The trading window is closed from November 8, 2025, to November 16, 2025.

Board Meeting Announcement

Natco Pharma has announced an upcoming meeting of its Board of Directors. The meeting is scheduled for Friday, November 14, 2025.

Agenda Highlights

During the meeting, the board will primarily focus on the following key items:

  • Consideration of the Unaudited Financial Results for the quarter and half-year ended September 30, 2025 (Q2 FY26).
  • Potential declaration of a 2nd interim dividend for the financial year 2025-26.

Trading Window Closure

In compliance with insider trading regulations, the trading window for dealing in the company’s securities will be closed for designated persons and their immediate relatives from November 8, 2025, to November 16, 2025, both days inclusive. The trading window will reopen on November 17, 2025.

Source: BSE

InvestyWise News
InvestyWise News
Covers market-moving news with speed and precision, delivering sharp insights to help readers stay ahead in the fast-paced world of stocks.

Latest articles

Related articles

Leave a reply

Please enter your comment!
Please enter your name here
Captcha verification failed!
CAPTCHA user score failed. Please contact us!